FDA Expands Risankizumab Label in Psoriatic Disease

(MedPage Today) -- The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older, AbbVie announced.
An interleukin (IL)-23 antagonist, risankizumab is...